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Some of the most commonly described genetic mutations in
human cancers occur within the p53 gene.  p53 is a tumour
suppressor that functions to protect the cell by regulating cell cycle
progression following DNA damage and other stresses (Levine,
1997). Mutations in the gene can increase the half-life of the
protein causing a loss of protective function as mutant protein
accumulates in the nuclei of tumour cells. The consequences of the
overexpression of mutant protein are not fully understood but have
been shown, in some instances, to lead to an immune response
characterized by the production of anti-p53 auto-antibodies
(Angelopoulou et al, 1994; Lubin et al, 1995). 
Anti-p53 antibodies have been detected in the serum of patients
with a range of cancers. However, not all patients with cancer
develop anti-p53 antibodies. The frequency varies depending on
the type of assay employed and the patient sampling criteria. Anti-
p53 antibodies have been detected in up to 26% of lung, 19% of
pancreatic, 17% of bladder, 13% of breast, 26% of colorectal and
46% of ovarian cancers (Lubin et al, 1995; Hammel et al, 1999;
Vogl et al, 1999). 
A lot of interest has been generated in anti-p53 antibodies in the
hope that they may serve as diagnostic markers or prognostic
indicators of disease severity. Recent work has shown that breast
(Lenner et al, 1999), lung (Lai et al, 1998), gastric (Wu et al, 1999)
and urological (Lang et al, 1998) cancer patients with anti-p53
antibodies had a significantly poorer prognosis than p53 antibody-
negative patients. However, in other forms of cancer such as head
and neck (Gottschlich et al, 1999), non-small cell lung (Mitsudomi
et al, 1998), ovarian (Gadducci et al, 1999), and gastric cancer
(Nakajima et al, 1999) the presence of antibodies against p53
showed no correlation with patient prognosis. Interestingly, it has
been shown for a sub-set of patients with pancreatic cancer
(Gansauge et al, 1996) and with hepatocellular cancer (Saffroy
et al, 1999) that the presence of p53 antibodies is associated with a
relatively ‘good prognosis’. It seems clear that the importance
of p53 auto antibodies as a prognostic indicator is likely to be
dependent on tumour type. 
MM is an incurable cancer associated with exposure to asbestos.
MM is characterized by a long latency period and diagnosis at an
advanced stage. It is highly resistant to both chemotherapy and
radiotherapy, with poor prognosis; the mean survival time
following presentation is 9 months (Musk et al, 1992). MM is
generally considered to be non-immunogenic or at best partially
immunogenic because immunization of mice with irradiated MM
cells confers little or no protection to a tumorigenic rechallenge.
There is however, good evidence for a weak anti-tumour response
in patients. Up to 20% of patients respond to IFN α or GMCSF
treatment (Upham et al, 1993; Davidson et al, 1998) and the
majority of MM patients exhibit anti-tumour antibody responses.
Antibody responses to native tumour antigens can be demon-
strated in up to 30% of patients by Western blot (Robinson et al,
1998). Using SEREX, we have shown that private specificities
dominate this response and that the complexity of the response
increases as the tumour grows, perhaps indicating thresholds that
are crossed through increasing antigen concentration (Robinson et
al, 2000). In all of these studies, we have restricted our analyses to
class-switched IgG isotypes as an indication of T cell recognition
of the antigen. 
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Summary Malignant mesothelioma (MM) generally occurs as a pleural tumour, related to the inhalation of asbestos fibres. It is highly
aggressive and largely unresponsive to treatment. The incidence of MM is particularly high in Western Australia because of the extensive blue
asbestos mining operations that occurred in the north of the state until 1966. MM is unusual in that mutations in the tumour suppressor gene
p53 are rarely observed, whilst over-expression of p53 protein is common. As the level of antibodies directed against p53 is thought to be of
prognostic value in some cancers and as MM is known to be immunogenic, we studied a cohort of Western Australian patients to determine
the prevalence of anti-p53 antibodies and their value as diagnostic markers or prognostic indicators. 6/88 (7%) of patients had high titres
(>2 SD above the mean of controls) of anti-p53 antibodies. There was no correlation between antibody titre and survival. Although 3/38 (8%)
of sera obtained from patients exposed to asbestos but prior to a diagnosis of MM contained antibodies, the same proportion of sera obtained
from patients exposed to asbestos but who remained disease free also contained antibodies (2/40; 8%). Sera collected sequentially
demonstrated a profound temporal stability in the titre of anti-p53 antibodies in patients with MM throughout the course of their illness. These
results show that anti-p53 antibodies are observed only at a low frequency in the sera of MM patients and where they do occur, their elicitation
is an early event that may be unrelated to antigen load. The occurrence of anti-p53 antibodies does not serve as either a useful prognostic or
diagnostic indicator in MM. © 2001 Cancer Research Campaign http://www.bjcancer.com
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doi: 10.1054/ bjoc.2000.1529, available online at http://www.idealibrary.com on  http://www.bjcancer.comMM rarely, if ever, exhibit mutations in the p53 gene (Metcalf et
al, 1992; Andersson et al, 1995; Lechner et al, 1997; Mor et al,
1997; Lee and Testa, 1999; Mayall et al, 1999), however, the
proportion of tumours reported to over-express p53 is relatively
high, with frequencies that range from 25% (9 out of 36) (Ramael et
al, 1992) to 85.7% (30 out of 35) (Esposito et al, 1997). In normal
cells, wild-type p53 is present at low levels because the protein is
very rapidly degraded following synthesis (Ashcroft and Vousden,
1999). Mutation of p53 often results in the synthesis of a stabilized
protein that has a much longer half-life than that of the wild-type
protein, therefore, immunohistochemical techniques are generally
employed to detect mutant p53 (Angelopoulou et al, 1994; Lubin et
al, 1995). There is, therefore, a discrepancy between findings of
wild-type p53 and over-expression of p53 protein in MM, and the
reasons for this are not clear. However, the over-expression of p53
in MM may elicit anti-p53 antibodies which may provide an impor-
tant surrogate marker of disease severity. A recent study showed
that MM patients had anti-p53 antibody titres that were not
different from controls (Schneider et al, 1999), however the sample
size was small (n=5), so we examined the prevalence of antibodies
to p53 in a larger sample of MM patients seeking to correlate anti-
body levels with clinical outcome. Early diagnosis of MM may
help to improve the poor prognosis if improved treatment can be
applied. We, therefore examined anti-p53 antibodies in pre-diag-
nosis sera to determine if their occurrence might provide an early
indication of the disease. Finally, because there are no surrogate
markers of disease progression, we examined whether antibody
levels paralleled antigen load. 
MATERIALS AND METHODS 
Sera 
Blood was obtained from patients presenting at the respiratory
clinics at Sir Charles Gairdner Hospital (Perth, Western Australia)
and from normal healthy laboratory volunteers. The procedures
were approved by the Human Rights Committee of the University
of Western Australia and fulfilled NH&MRC Guidelines on
Human Experimentation and informed consent was obtained from
all patients before enrolment in the study. Clotted blood was
centrifuged at 3000 g for 10 min and serum stored in aliquots at
–80˚C before use. Diagnosis of MM was made from history and by
radiological examination and confirmed by cytology and immuno-
histochemistry. The patients (76 male and 12 female) were aged
between 39 and 81 years at the time samples were taken (mean
63.4 ± 9.6 years). The normal controls (18 male and 7 female)
were aged between 24 and 74 years (mean 45.2 ± 17 years). As
part of an independent public health study, sera were collected
annually from individuals previously exposed, either occupation-
ally or environmentally, to blue asbestos in the Wittenoom area of
Western Australia, some of these individuals went on to develop
MM (de Klerk et al, 1998; Musk et al, 1998). A subset of this
serum bank was used in the current study, serving as an age-
matched, asbestos-exposed control population and as a source of
pre-diagnosis sera. 
Cell lines and tissue culture 
The human MM cell lines, JU77, LO68, NO36, ONE58 and
STY51 were all derived from the pleural fluid of patients with
disease (Manning et al, 1991). The human lung adenocarcinoma,
A549, and the human colon cancer line HT29 were purchased
from the American Type Culture Collection (Manassas, VA). Cells
were cultured in RPMI-1640 (Life Technologies, Melbourne,
Australia) supplemented with 20 mM HEPES, 5 × 10–5 M 2-
mercaptoethanol, 10% foetal calf serum (Life Technologies) and
incubated at 37˚C in a water-saturated atmosphere of 5% CO2 in air. 
Western blot analysis 
Peripheral blood lymphocytes (PBL) were obtained from
heparinized venous blood by Ficoll-Paque (Pharmacia, Upsala,
Sweden) density gradient centrifugation. Cells from log phase in
vitro cultures were harvested by centrifugation. Cell lysates were
separated by electrophoresis and blotted onto membranes as previ-
ously described (Robinson et al, 1998), with p53 expression exam-
ined using a murine anti-p53 antibody (DO-1, Santa Cruz Biotech,
CA) at a 1:5000 dilution in PBS. The intensity of signal produced
following visualization of bound antibody with chemiluminescence
(ECL; Amersham Life Sciences, England) was determined using
ImageQuant software (Molecular Dynamics, Sunnyvale, CA). 
ELISA 
Wells of a 96-well microtitre plate (COSTAR, Corning) were
coated with p53 (Santa Cruz Biotechnology) at 250 ng ml–1 in
100 mM NaHCO3, pH 8.2 overnight at 4˚C. Wells were washed
three times with PBST, blocked for 1 h at 37˚C with 75 µl well–1,
PBS, 20% normal horse serum and re-washed. Serum samples
were diluted at 1/50 in PBST then applied in duplicate to p53-
coated and control (buffer only) plates, a double dilution was
performed so that samples were also assessed at a 1/100 dilution.
Plates were incubated for 1 h at 37˚C then washed. Bound anti-
bodies were detected following 1 h, 37˚C incubation with alkaline
phosphatase conjugated anti-human IgG (Promega) and visualized
with 50 µl well–1 1 mg ml–1 pNPP (Sigma) in 100 mM NaHCO3,
100 mM Na2CO3 pH 9.8, 2 mM MgCl2. Absorbance was measured
on a SpectrMax 250 plate reader at 405 and 490 nm and presented
as L1–L2. Relative absorbance was determined by subtracting
values for control plates from p53 plates. The ELISA was highly
reproducible and variance between duplicates did not exceed 5%.
We were able to demonstrate the specificity of the assay by
complete inhibition of binding with recombinant p53 but no inhi-
bition with an unprogrammed bacterial lysate (data not shown). 
RESULTS 
p53 protein expression 
Using an antibody that recognizes both mutant and wild-type
human p53, p53 was detected in all samples tested by Western blot-
ting. In normal PBL, wild-type p53 was of low abundance (Figure 1).
Low p53 levels were also demonstrated in the A549 lung adenocar-
cinoma cell line, in which the p53 gene is unmutated. Mutant p53
has a longer half-life than the wild-type protein (Angelopoulou et
al, 1994; Lubin et al, 1995) so the presence of high levels of p53
protein may indicate the presence of a mutated p53 gene (Figure 1;
HT29 cells carry a GA mutation at codon 273). 
For comparison, one tenth of the amount of HT29 protein
was examined compared to the other cell lysates. All of the human
MM cell lines examined over-expressed p53 protein compared
with PBL (Figure 1). There was variation in the level of p53
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over expression with ONE58 cells having the highest levels of p53
in the MM cell lines, followed by STY51 and NO36 cells. The
expression of p53 in JU77 and LO68 was lower than that of the
other over-expressing cell lines but still >5 and >2-fold higher, as
determined by densitometric comparison (data not shown) than
that of normal human PBL. 
Anti-p53 antibodies in MM 
There was substantial variation in the titre of anti-p53 antibodies in
the control population of healthy individuals, with the mean relative
absorbance of this population being 0.344 (±0.25). No segregation
of the control population into sub-populations could be demon-
strated on the basis of age, sex or smoking status (data not shown).
The mean serum anti-p53 levels in 88 patients with MM, (0.244
±0.23) was not significantly different from controls. However, 6
patients had antibody levels greater than 2 standard deviations
above the mean of the control population (Figure 2). No correlation
between anti-p53 antibody levels and patient survival was demon-
strated. Survival of these 6 patients ranged from 3 months after
diagnosis to 2.5 years after diagnosis (patient still alive). 
The titre of anti-p53 antibodies was also determined in sera
from people that had been exposed to asbestos, but at the time the
samples were taken did not have MM. This asbestos-exposed
group was further divided into those that displayed no evidence of
disease at the time of the writing of this report, and those that had
developed MM. The mean relative absorbance of asbestos-
exposed/healthy samples was 0.321 (±0.28) and of asbestos-
exposed/pre-MM samples was 0.306 (±0.23), which was not signif-
icantly different. Furthermore, there was no significant difference
between the asbestos-exposed cohort and either controls or MM
patients. Two individuals from the asbestos-exposed/healthy cohort
and 3 individuals from the asbestos-exposed/pre-MM cohort exhib-
ited titres above the significance line (Figure 2). 
Temporal changes in anti-p53 titre 
Sera taken before the clinical diagnosis of disease were not avail-
able from the 6 MM patients with anti-p53 antibodies. However,
serial sera samples were available from some individuals exposed
to asbestos who then went on to develop MM. Of the 13 individu-
als examined, none showed a greater than 0.2 Unit change in levels
of anti-p53 antibodies over a 3 to 4 year period (Figure 3A and
data not shown). Similarly, the two individuals with elevated p53
antibodies (Figure 2), who were exposed to asbestos but had not,
so far, developed MM showed no change in anti-p53 levels over
time (Figure 3B). 
Importantly, no increase of greater than 0.2 Units in anti-p53
antibody levels was demonstrated in any of 17 patients examined
at various times through the progression of their disease. Where
several samples were available the anti-p53 titre was seen to be
remarkably consistent (Figure 3C). 
DISCUSSION 
6 of 88 patients (7%) in this study with MM had elevated levels of
anti-p53 antibodies present in their sera. Compared to other forms
of cancer this is a low frequency (Lubin et al, 1995). However,
there is a large variation in anti-p53 antibody levels reported
between tumour types possibly reflecting the different properties
of the malignancy which could clearly be the case for MM. 
Antibodies to p53 probably arise in response to increased
antigen load, secondary to the unusually large amounts of protein
that accumulate because of mutations in the gene. It is clear that in
general, mutations are not a pre-requisite for an autoantibody
response and, indeed, there are reports in the literature of p53 anti-
bodies in the absence of genetic mutation (Angelopoulou et al,
1994). Overexpression of translation initiation factor (eIF)-4
gamma, as a consequence of gene amplification has been shown to
correlate with an immune response in patients with squamous cell
lung carcinoma (Brass et al, 1999). Similarly a serologic response
to HER2/neu, an oncogene amplified in certain cancers strongly
supports the notion that overexpression is sufficient to initiate a
humoral immune response in some individuals (Cheever et al,
1995). Such is probably the case for p53 antibodies generated in
MM patients, although the p53 status of any of the patients in this
study is not known. Further work is necessary to establish if there
is a causal relationship between the level of expression and the
elicitation of a humoral response. 
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Figure 1 Expression of p53 protein by normal cells and MM cell lines.
Lysates were prepared from the human lung cancer cell line (A549), the
colon cancer cell line (HT29), various MM cell lines (JU77, LO68, NO3,
ONE58 and STY51) and from normal peripheral blood lymphocytes (PBL).
Proteins were separated electrophoretically and blotted onto nitrocellulose.
The amount of p53 protein in each lysate was determined by exposing the
blot sequentially to a specific monoclonal anti p53 antibody (DO-1), rabbit anti
mouse IgG labelled with HRP and to the ECL development reagent. Note:
HT29 lysate was diluted 1/10 
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Figure 2 Anti-p53 antibodies in MM. Serum levels of anti-p53 antibodies in
healthy controls, MM patients, and individuals with a history of exposure to
asbestos. Individuals exposed to asbestos were further divided into those
that later went on to develop MM and those who remained disease-free at the
time of this study. Presented is the mean absorbance of duplicates of a 1/50
dilution of serum measured by ELISA. The horizontal dashed line denotes an
absorbance value 2 SD above the mean for the control population. The mean
absorbance for each population is shown by a solid line with double headed
arrows The p53 gene is rarely mutated in MM yet overexpression of
p53 protein occurs frequently (Esposito et al, 1997; Lee and Testa,
1999; Mayall et al, 1999; and data shown here). In normal cells,
p53 is present at low levels because the protein is very rapidly
degraded following synthesis (Ashcroft and Vousden, 1999).
Protein accumulation could result from a defect in this pathway or
in one of the pathways that stabilize or activate p53. Stabilization
of p53 can result following inhibition of the Mdm2-mediated
degradation pathway, modulation of p53 phosphorylation, cyto-
plasmic sequestration, or expression of inhibitors of Mdm2 func-
tion such as p14ARF (Ashcroft and Vousden, 1999). In MM cell
lines, Mdm2 appears to function normally (Ungar et al, 1996) and
p14ARF is located on a chromosomal region that is frequently
deleted in MM (Murthy and Testa, 1999) which suggests that p53
protein accumulation results for other reasons. 
SV40 like sequences have been found in up to 60% of MM and
also in several other relatively rare malignancies (Carbone et al,
1999). SV40 infection causes the in vitro transformation of normal
cells. Transformation occurs predominantly through the action of
the SV40 large tumour (T) antigen. T antigen has many functions
including the sequestration and inactivation of the tumour
suppressor gene products, p53 and Rb. Interestingly, transfection
of T antigen into normal cells results in accumulation of p53
protein, this p53 is subsequently bound to T antigen in large
complexes (Gonin et al, 1999). Recently, we have demonstrated
the presence of SV40-like sequences in the MM cell lines exam-
ined in the current work (McLaren et al, 2000), allowing for the
possibility that the p53 accumulation in these cell lines could be a
result of infection with SV40 or a related virus. 
p53 serum antibodies have been used as prognostic indicators in
several different types of cancer. Because of the lack of treatment
options for MM and the short mean survival of 9 months the
usefulness of anti-p53 antibodies in MM appears limited. In the
present study, only 6 of the 88 patients sera examined had elevated
p53 antibodies and there was no correlation between antibody
levels and survival. 
One of the major objectives of this study was to determine the
utility of anti-p53 antibodies as diagnostic or prognostic surrogate
markers of MM. A cheap and reliable test for MM would have
immense value for those people in the ‘at-risk’ population by
virtue of their prolonged exposure to asbestos. Given the poor
prognosis of individuals with MM it may prove useful if treatment
options could be explored earlier. Also, given the experimental
nature of newer therapeutic options, markers of disease progres-
sion would be an invaluable adjunct to clinical trials. However, the
present study showed no difference between individuals that had
been exposed to asbestos but were segregated upon the basis of
whether or not they went on to develop MM. And furthermore,
there was no increase in p53 antibody levels over time in these
populations. Thus anti-p53 antibody levels do not serve as a diag-
nostic indicator for MM. 
The clinical relevance of antibodies against p53 appears to be
dependent on the tumour type. In the case of MM, anti-p53 anti-
bodies are observed only at a low frequency in the sera of patients
and their presence does not serve as either a prognostic or diag-
nostic indicator. 
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